Home › Research › Laboratory science
Alzheimer's disease transcriptional landscape in ex vivo human microglia
Kosoy R, Fullard JF, Bendl J, Kleopoulos SP, Shao Z, Argyriou S, Mathur D, Psychogyiou K, Malakates P, Vicari J, Ma Y, Humphrey J, et al.. Nature Neuroscience, 2025-08-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Microglia are resident immune cells of the brain and are implicated in the etiology of Alzheimer's disease (AD) and other diseases. Yet the cellular and molecular processes regulating their function throughout the course of the disease are poorly understood. Here, we present a transcriptional analysis of primary microglia from 189 human postmortem brains, including 58 healthy aging individuals and 131 with a range of disease phenotypes, such as 63 patients representing the full clinical and pathological spectra of AD. We identified changes associated with multiple AD phenotypes, capturing the severity of dementia and neuropathological lesions. Transcript-level analyses identified additional genes with heterogeneous isoform usage and AD phenotypes. We identified changes in gene-gene coordination in AD, dysregulation of coexpression modules and disease subtypes with distinct gene expression patterns. Taken together, these data further our understanding of the key role that microglia have in AD biology and nominate candidates for therapeutic intervention.
What this study adds
Evidence grade: Early
This is a case-control study of 189 participants. Analysing primary microglia from 189 human postmortem brains, this study found gene expression changes associated with multiple Alzheimer's disease phenotypes, including dementia severity and neuropathological lesions, plus changes in gene-gene coordination and disease subtypes. It furthers understanding of microglia in Alzheimer's disease biology and nominates candidate targets, but identifies no treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kosoy, R., Fullard, J. F., Bendl, J., Kleopoulos, S. P., Shao, Z., Argyriou, S., et al. (2025). Alzheimer's disease transcriptional landscape in ex vivo human microglia. Nature Neuroscience. https://doi.org/10.1038/s41593-025-02020-2
Vancouver
Kosoy R, Fullard JF, Bendl J, Kleopoulos SP, Shao Z, Argyriou S, et al. Alzheimer's disease transcriptional landscape in ex vivo human microglia. Nature Neuroscience. 2025. doi:10.1038/s41593-025-02020-2. PMID: 40760184.
BibTeX
@article{kosoy2025-40760184,
author = {Kosoy, R. and Fullard, J. F. and Bendl, J. and Kleopoulos, S. P. and Shao, Z. and Argyriou, S. and Mathur, D. and Psychogyiou, K. and Malakates, P. and Vicari, J. and Ma, Y. and Humphrey, J. and others},
title = {{Alzheimer's disease transcriptional landscape in ex vivo human microglia}},
journal = {Nature Neuroscience},
year = {2025},
doi = {10.1038/s41593-025-02020-2},
pmid = {40760184},
url = {https://doi.org/10.1038/s41593-025-02020-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We identified changes associated with multiple AD phenotypes, capturing the severity of dementia and neuropathological lesions.
- Taken together, these data further our understanding of the key role that microglia have in AD biology and nominate candidates for therapeutic intervention.
Why it matters
Analysing primary microglia from 189 human postmortem brains, this study found gene expression changes associated with multiple Alzheimer's disease phenotypes, including dementia severity and neuropathological lesions, plus changes in gene-gene coordination and disease subtypes. It furthers understanding of microglia in Alzheimer's disease biology and nominates candidate targets, but identifies no treatment, cure or prevention.
Study details
- Study designcase-control
- Participants189
- Evidence strengthEarly
How this study scored 59/100
Published in a leading specialty journal, and it is a case-control study. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 58 of the 98 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Neuroscience) |
| Journal's citation record | 4 / 4 | Nature Neuroscience: journal h-index 593 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 189 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 18 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Panos Roussos: h-index 94 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Icahn School of Medicine at Mount Sinai: institution h-index 1,331 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40760184) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 58 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 98 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41593-025-02020-2
- PubMed: 40760184
- Original source →
- Free full text: researchsquare.com →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Laboratory science from nearby years
Also in Laboratory science
6 studies in the library are filed under Laboratory science with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Laboratory science hub.